Across TCGA pan-cancer cohorts, SLC39A1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC39A1 data layer compared with 25 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC39A1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC39A1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.
HNSC and LUAD are the cancer types where SLC39A1 mass-spec protein most reproducibly stratifies survival.